Novocure Ltd. (NASDAQ: NVCR), Zai Lab Ltd.’s (NASDAQ: ZLAB, HKG: 9688) Swiss oncology partner, announced FDA clearance for Optune Pax, its portable Tumor Treating Fields (TTFields) device, for locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel. The Phase III PANOVA-3 data demonstrated significant overall survival improvement (16.2 vs. 14.2 months) and pain-free survival benefit (15.2 vs. 9.1 months), positioning TTFields as a new standard-of-care in this high-mortality malignancy.
Innovative medical device pathway in China; NRDL negotiation for cancer supportive care category
Global Alignment
FDA approval validates technology; supports Zai Lab partnership valuation and ex-China rights discussions
Forward‑Looking Statements This brief contains forward‑looking statements regarding Optune Pax NMPA approval timelines in China, Zai Lab’s pancreatic cancer commercialization strategy, and TTFields market expansion in solid tumors. Actual results may differ due to regulatory review delays, physician adoption of device-based oncology therapy, and reimbursement negotiation outcomes for medical devices in China.-Fineline Info & Tech
